Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

bedaquiline

Data-driven healthcare communications

Data analysis is everywhere, and the role it plays in our lives is increasing exponentially. From deciding what car to purchase to what medicine will be prescribed for us, the...

Lucid Group Communications Limited

- PMLiVE

US COVID-19 booster programme expanded

The FDA and CDC have given the green light to an expansion of the US COVID-19 booster programme to include another shot of the Moderna and J&J vaccines as well...

- PMLiVE

The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines

J&J’s data showed that a second shot of its vaccine boosts protection to 94% against symptomatic moderate-to-severe infection when administered two months after the first dose

- PMLiVE

Janssen’s RSV vaccine provides high protection against respiratory infections

The phase 2b data showed the RSV vaccine provided 80% protection against lower respiratory infections in adults aged 65 and older

- PMLiVE

bluebird bio gears up for split

The company has filled its coffers with $75m in new funding and hired new leaders to support its split into two separate companies, bluebird bio and 2seventy bio

- PMLiVE

FDA nod for Janssen schizophrenia treatment Invega Hafyera

The phase 3 study results showed that 92% of patients were relapse-free after 12 months

- PMLiVE

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

In 2017, Pfizer filed a lawsuit against J&J alleging that the company undertook anticompetitive practices in a bid to protect Remicade

- PMLiVE

J&J, distributors reach $26bn settlement to address the opioid crisis in the US

The proposed agreement would resolve claims of both states and local governments in the US

- PMLiVE

AZ, J&J to research modifications to COVID-19 vaccines over rare blood clot issues

Researchers to explore potential of modifications to vaccine to reduce or remove risk of rare blood clots

- PMLiVE

FDA lists rare neurological condition as potential side effect of J&J’s COVID-19 vaccine

Guillain-Barré syndrome has been reported in 100 people who have received the vaccine in the US

- PMLiVE

J&J’s COVID-19 vaccine shows ‘strong’ activity against Delta variant

Vaccine produces durable immune responses lasting up to eight months

- PMLiVE

Rare diseases: why they can be so difficult to identify

Symptoms shared with more common diagnoses can make it more difficult to spot underlying rare diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links